JPRN-jRCT2080221134未知1 期
A phase I and pharmacokinetic study to determine the safety of ET-743 administered as a continuous intravenous infusion over 24 hours every 21 days in patients with soft tissue sarcoma.
适应症
试验速览
- 阶段
- 1 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1)Patients who have a histologically confirmed soft tissue sarcoma.
- •2)Patients who have failed the standard therapy.
排除标准
- •1)Serious concomitant illness.
- •2)Prior therapy-related toxicity.
研究者
相似试验
已完成
1 期
Pharmacokinetic profile, safety and tolerability of Sildenafil (REVATIO®) in cardiac surgery patients with chronic kidney diseaseCardiac surgery patients with chronic kidney diseaseUrological and Genital DiseasesChronic kidney diseaseISRCTN37719011niversity of Leicester (UK)36
已完成
不适用
A phase I study to investigate the pharmacokinetics, safety and tolerability of four different dosing regimens of GRC 17536 in healthy male volunteers using tablet formulation.Pijn en luchtwegaandoeningenPain and respiratory conditionsNL-OMON42613Glenmark Pharmaceuticals SA28
已完成
1 期
A single-center study of the safety, tolerability and pharmacokinetics of a single concentration of topical SM04554 (0.25% concentration) solution in male subjects with androgenetic alopecia.Androgenetic alopecia (AGA)Skin - Dermatological conditionsMetabolic and Endocrine - Other endocrine disordersHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersACTRN12615000980538Samumed Pacific Pty Ltd25
进行中（未招募）
1 期
A Phase I study to investigate the pharmacokinetics and ECG effects of two single ascending doses of linaprazan glurate given as oral tablets to healthy subjectsErosive Gastroesophageal Reflux Disease (eGERD)MedDRA version: 20.1Level: LLTClassification code: 10017924Term: Gastroesophageal reflux Class: 10017947CTIS2024-516261-36-00Cinclus Pharma Holding AB (publ)63
已完成
Unknown
Studying the safety and the pharmacokinetics after single dosing of KDF2001 in healthy adultEndocrine, nutritional and metabolic diseasesKCT0009163Kyung Dong Pharmaceutical40